Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides calories and serves as a source of energy. Sodium chloride provides electrolytes to maintain osmolality and fluid balance.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Intravenous fluid replacement and caloric supply in patients who cannot take oral fluids,Treatment of dehydration and electrolyte imbalances,Maintenance fluid therapy
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion; rate determined by fluid and electrolyte needs; typical adult rate 100-200 m L/hour.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Dextrose: not applicable (endogenous substrate). Sodium: 10-20 minutes (rapid distribution); chloride parallels sodium. Clinical context: renal function prolongs half-life of infused components.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Dextrose is metabolized via glycolysis and the citric acid cycle to produce ATP. Sodium chloride is not metabolized; it is excreted renally.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Dextrose is metabolized to carbon dioxide and water; sodium and chloride are excreted renally. >90% of water and electrolytes are eliminated via kidneys. Minimal fecal or biliary elimination.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Dextrose: negligible. Sodium: negligible (<5%). Chloride: negligible. No significant protein binding.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Dextrose: 0.2-0.3 L/kg (total body water). Sodium: 0.6-0.7 L/kg (extracellular fluid). Chloride: similar to sodium. Clinical meaning: reflects distribution into extracellular space.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intravenous: 100%. Not applicable for other routes.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
GFR <30 m L/min: use with caution; monitor fluid and electrolyte status; reduce infusion rate to avoid volume overload.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific adjustment required for Child-Pugh classification; monitor for fluid retention.
No dosage adjustment required for hepatic impairment.
Weight-based dosing: 5-20 m L/kg/day as maintenance fluid; adjust based on age, weight, and clinical condition.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Caution with volume overload; initiate at lower infusion rates (50-100 m L/hour) and monitor cardiopulmonary status.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
None.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Hyperglycemia in patients with diabetes mellitus or glucose intolerance,Fluid overload in patients with cardiac or renal impairment,Electrolyte abnormalities such as hypernatremia or hyponatremia,Extravasation risk with peripheral administration,Monitor serum glucose and electrolytes regularly
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hyperglycemia and hyperosmolar coma,Severe electrolyte disturbances (e.g., hypernatremia),Anuria or severe renal impairment requiring fluid restriction,Known hypersensitivity to dextrose or sodium chloride
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No significant food interactions, but patients on a salt-restricted diet or with diabetes should monitor sodium and sugar intake closely per physician guidance.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Dextrose 10% and sodium chloride 0.9% are normal constituents of blood and are not teratogenic. No increased risk of fetal malformations is expected when used as clinically indicated in any trimester. However, maternal hyperglycemia (from excessive dextrose administration) may cause fetal hyperinsulinism and neonatal hypoglycemia if given near term.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Dextrose and sodium chloride are endogenous substances present in breast milk. No adverse effects on the breastfed infant are anticipated. M/P ratio not applicable as these are normal blood constituents; levels in milk reflect maternal plasma levels. However, large intravenous doses may transiently alter milk composition (e.g., increase glucose).
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
No specific dose adjustments required for pregnancy per se. However, pregnant patients have increased plasma volume and glomerular filtration rate, which may increase clearance of glucose and electrolytes. Monitor serum sodium and glucose to guide replacement. Avoid excessive dextrose loads to prevent maternal hyperglycemia and fetal hyperinsulinism, especially near term.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
This combination is isotonic and provides 170 kcal/L. Use with caution in patients with heart failure, renal impairment, or hypernatremia. Monitor serum sodium and glucose levels, especially in patients with diabetes or hyperglycemia. Not suitable for resuscitation unless combined with colloid or blood products.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
This IV solution provides water, sugar, and salt to maintain hydration and electrolyte balance.,Tell your doctor if you have kidney disease, heart failure, diabetes, or high blood pressure.,Report any swelling, shortness of breath, or rapid weight gain during treatment.,Do not consume additional salt or sugar without medical advice while receiving this solution.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides calories and serves as a source of energy. Sodium chloride provides electrolytes to maintain osmolality and fluid balance.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by fluid and electrolyte needs; typical adult rate 100-200 m L/hour.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose 10% and sodium chloride 0.9% are normal constituents of blood and are not teratogenic. No increased risk of fetal malformations is expected when used as clinically indicat. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.